Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

50.71 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
News headline image
Want to Build Real Wealth in Healthcare? These Stocks Are Worth Considering ↗
These companies are leaders in their fields. 
Via The Motley Fool
News headline image
What's the Next Big Thing After GLP-1 Drugs? CRISPR Therapeutics May Have the Answer. ↗
The biotech's candidate may treat a great number of illnesses that have one thing in common. 
Via The Motley Fool
News headline image
Should You Forget This High-Yield Pharma Stock and Buy a Growth Name Instead? ↗
This particular player has seen its yield rise in recent years. 
Via The Motley Fool
News headline image
3 Growth Stocks That Could Generate 10X Returns ↗
These stocks come with risk, but they also have some exciting long-term growth opportunities. 
Via The Motley Fool
Topics Cannabis Law Enforcement
News headline image
3 Biotech Stocks That Could Benefit from the Patent Cliff ↗
Via MarketBeat
Topics Intellectual Property
News headline image
CRISPR Therapeutics Has Major Catalysts Ahead. Is This Biotech Stock a Screaming Buy? ↗
We'll know more about the company's medium-term prospects by the end of the year. 
Via The Motley Fool
News headline image
2 Billion Reasons to Love CRISPR Therapeutics Right Now ↗
The company's strong cash position gives investors confidence in the gene-editing stock. 
Via The Motley Fool
News headline image
This Biotech Has a Pipeline That Could Redefine Its Entire Therapeutic Area ↗
Innovation often pays off, and this biotech could cement its innovative capabilities in the next few years. 
Via The Motley Fool
News headline image
Is This Biotech Stock Your Best Shot at Building a Millionaire-Making Position? ↗
With an approved treatment in commercial stages and new drug candidates generating clinical trial results, this biotech has attracted a big Investor. 
Via The Motley Fool
Topics ETFs
News headline image
CRISPR Therapeutics Stock: Is It a Bargain Buy Right Now? ↗
The gene-editing stock has been in a tailspin of late. 
Via The Motley Fool
News headline image
Vertex Pharmaceuticals (VRTX): The Evolution of a Biotech Powerhouse in 2026
As of March 20, 2026, Vertex Pharmaceuticals (NASDAQ: VRTX) has officially transcended its long-held identity as "the cystic fibrosis (CF) company." For over a decade, the Boston-based biotech giant... 
Via Finterra
Topics Intellectual Property
News headline image
Is CRISPR Therapeutics Stock a Buy Now? ↗
We will know even more about the company's prospects in a year as it releases clinical data for various pipeline candidates. 
Via The Motley Fool
News headline image
3 Monster Stocks to Hold for the Next 10 Years ↗
They're names worth holding for far longer, but the coming decade could prove particularly fruitful for these companies. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
This Is Why CRISPR Therapeutics Stock Is Tumbling on Tuesday ↗
Current shareholders were thrown an unexpected curveball that they actually should have been expecting. 
Via The Motley Fool
News headline image
Why Is CRSP Stock Falling Pre-Market Today? ↗
The company plans to issue $350 million in convertible senior notes that are scheduled to mature in 2031. 
Via Stocktwits
News headline image
RIVN Stock Gains 4% Pre-Market After TD Cowen Upgrade: Analyst Sees Strong Demand For Upcoming R2 Models ↗
The firm believes the new lineup could significantly expand Rivian's addressable EV market. 
Via Stocktwits
Topics Electric Vehicles
News headline image
Forget CRISPR Therapeutics: This Gene‑Editing Player Already Boasts the Profits It Dreams Of ↗
These two biotechs have a lot in common. Their differences are even more pronounced. 
Via The Motley Fool
News headline image
Is CRISPR Therapeutics Stock Too Risky to Buy Right Now? ↗
CRISPR isn't profitable, but it does have an approved gene therapy treatment with loads of potential. 
Via The Motley Fool
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
Could these three stocks be Cathie Wood's next big winners? 
Via The Motley Fool
Topics ETFs
News headline image
Is CRISPR Therapeutics Stock Going to $0, or Will the Hype Pay Off? ↗
The past few years have been challenging for the biotech. 
Via The Motley Fool
News headline image
The Gene‑Therapy Breakthrough Story You'll Be Mad You Ignored at These Prices ↗
Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now. 
Via The Motley Fool
Topics ETFs
News headline image
2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall Street ↗
These biotech companies have catalysts ahead. 
Via The Motley Fool
News headline image
CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows ↗
Via MarketBeat
News headline image
Should You Buy Shares of CRISPR Therapeutics in February? ↗
The company could finally be ready to deliver on years of promise. 
Via The Motley Fool
News headline image
The Blastoff-Ready Biotech Stock You'll Kick Yourself for Not Buying in 2026 ↗
2026 could be a big year for this company. 
Via The Motley Fool
News headline image
Why CRISPR Therapeutics Stock Is Up Today (Despite Its Q4 Earnings Miss) ↗
A sales partner offered a ray of hope that this company couldn't for itself. 
Via The Motley Fool
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
Opportunity knocks thrice for the iconic growth investor. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Forget AI Stocks: This Biotech Could Cure What AI Can't Touch ↗
Artificial intelligence (AI) isn't the only industry with explosive growth potential. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Nasdaq, S&P 500 Futures Climb Ahead Of Apple Earnings: Why META, TSLA, MP, CRML, SER Are On Traders' Radar Today ↗
Retail sentiment on major ETFs such as SPY and QQQ remains ‘extremely bearish’ on Stocktwits. 
Via Stocktwits
Topics Artificial Intelligence ETFs Government
News headline image
Cathie Wood&#39;s Favorite Biotech Stock Is Under Pressure Amid Insider Sales And Slow Revenue Growth: Momentum Score Drops ↗
Swiss-American biotechnology company, CRISPR Therapeutics AG (NASDAQ: CRSP), has come under renewed pressure in recent weeks, amid insider sales, slow revenue growth, and weak adoption of its core... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.